LGVN — Longeveron Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1721484 ·
Last close
$2.37
Market Cap
$7.21M
52W High
$12.30
52W Low
$2.30
ADV30
143,615
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 287,000 | 182,000 | -6,171,000 | -6,073,000 | 15,487,000 | 10,077,000 | 5,085,000 |
| Mar 2026 | 398,000 | 264,000 | -4,775,000 | -4,736,000 | 21,210,000 | 15,758,000 | 5,183,000 |
| Dec 2025 | 365,000 | 257,000 | -5,399,000 | -5,444,000 | 10,261,000 | 4,661,000 | 4,586,000 |
| Sep 2025 | 137,000 | 125,000 | -7,310,000 | -7,221,000 | 15,557,000 | 9,244,000 | 5,591,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,318,000
Investing CF
$-465,000
Financing CF
$20,214,000
CapEx
$-465,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,047,000
Inventory
—
Receivables
$68,000
ST Investments
$0
EBIT TTM
$-22,881,000
Pretax Income TTM
$-22,429,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,187,000
EBITDA
$-22,440,000
Free Cash Flow
$-11,603,375
Enterprise Value
$13,873,491
Total Cash
$10,077,000
Total Debt
$581,000
Shares Out
3,043,297
Trailing EPS
$-10.00
Book Value
$3.28
ROE
-203.6%
ROA
-90.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,199,000 | -23,287,000 | -22,704,000 | 10,261,000 | 4,586,000 | 5,675,000 | -18,645,000 |
| Dec 2024 | 2,392,000 | -16,522,000 | -15,973,000 | 25,558,000 | 3,671,000 | 21,887,000 | -13,868,000 |
| Dec 2023 | 709,000 | -21,029,000 | -21,413,000 | 12,078,000 | 5,337,000 | 6,741,000 | -19,002,000 |
| Dec 2022 | 1,222,000 | -18,043,000 | -18,835,000 | 27,413,000 | 6,910,000 | 20,503,000 | -13,969,000 |
TTM Snapshot
Revenues TTM
$1,216,000
NetIncome TTM
$-22,429,000
OpCashFlow TTM
—
Assets (Latest)
$21,210,000
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INM | InMed Pharmaceuticals Inc. | $7.31M | $1.33 | — |
| TRAW | Traws Pharma, Inc. | $7.38M | $0.48 | — |
| FBLG | FibroBiologics, Inc. | $7.39M | $1.11 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $7.03M | $3.65 | — |
| APRE | Aprea Therapeutics, Inc. | $7.03M | $0.56 | — |
News headlines (Yahoo Finance, 1h cache)
Longeveron to Participate in Three Longevity/Aging Investment Conferences
2026-09-30 20:05 · Yahoo
LGVN Posts Disappointing Trial Results
2026-09-17 11:14 · Yahoo
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
2026-09-16 21:27 · Yahoo
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 13:15 · Yahoo
Longeveron Announces 1-for-10 Reverse Stock Split
2026-08-24 20:05 · Yahoo
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
2026-08-19 21:58 · Yahoo
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
2026-08-19 20:05 · Yahoo
LGVN at a Major Inflection Point
2026-08-13 12:07 · Yahoo
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
2026-08-03 20:05 · Yahoo
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
2026-07-23 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.